

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 34-16710-01

Docket or Reference number 030-11522

Amendment No. 09

Bethesda Hospital
2951 Maple Avenue
Zanesville, OH 43701

In accordance with letter dated June 26, 1985, License Number 34-16710-01 is amended as follows:

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

D. R. Boyse, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

J. S. Safko, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

D. B. Neeland, M.D.

Groups I, II, III and IV
Xenon-133
In vitro studies

W. F. Pomputius, M.D.

Licensed material of the types, quantities and forms specified in Sections 35.31(a) of 10 CFR 35 and 31.11(a) of 10 CFR 31 in accordance with the provisions of paragraphs (a) and (c) of Section 35.31, 10 CFR 35 and paragraphs (a), (c), and (d) of Section 31.11, 10 CFR 31.

John W. Steinberger, M.D.

Groups I, II and III
Soluble phosphorus-32 for treatment of polycythemia vera, leukemia and bone metastases
Xenon-133
In vitro studies

J. Greenspan, M.D.

Groups I, II and III
Xenon-133
Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
In vitro studies

8508070116 850717
REG3 LIC30
34-16710-01
PDR

COPY

2
mc30

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number 34-16710-01

Docket or Reference number 030-11522

Amendment No. 09

M. A. Graber, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

R. L. Mellon, M.D.

Groups I, II and III
Xenon-133
In vitro studies



For the U.S. Nuclear Regulatory Commission

Date July 17, 1985

Original Signed
By Evelyn R. Matson
Materials Licensing Section, Region III

COPY